Dealing with Stress...The Genentech Way

All large organizations have their own way to deal with 'stress'. This case explains how Genentech responds to stress. Genentech is the first biotechnology company founded in 1976 by biochemist Herbert W. Boyer and venture capitalist Robert A. Swanson. Another major leading company, G enentech, wants to become a leading biotechnology company. It is recognized as a very friendly company for its human resource policy and its human treatment. In 2007, Genentech 's CEO Arthur Levinson wanted to make his company a good place to increase awareness of work, industry and magazines.

In 1976 Genentech, the first genetic engineering company, was founded by Herbert Boyer and Robert Swanson, and one year later, it produced human protein (somatostatin) in E. coli. Genentech announced the production of genetically modified human insulin in 1978. In 1980, the US Supreme Court ruled that a genetically modified life could be patented with Diamond v. Chakrabarty case. Insulin produced by bacteria was released by the Food and Drug Administration (FDA) in 1982.

In 1980, Genentech, a biotechnology company in the United States, developed biosynthetic human insulin. Insulin is isolated from genetically modified bacteria that produce large amounts of insulin (bacteria include human genes for synthesis of synthetic human insulin). Purified insulin is distributed to pharmacies for use by diabetic patients. Initially, this development has not been seen as a clinically important development by the medical community. However, by 1996, the advent of insulin analogues greatly improved the properties of absorption, distribution, metabolism and excretion (ADME), which was clinically meaningful based on this early development of biotechnology.

In the late 1970s, insulin was still produced in 50 years and 1 pound of insulin was extracted by impregnating the porcine pancreas - 23,000 animals. Eli Lilly and Co., a leading manufacturer of insulin drugs, wants a better approach and seeks a new approach. A small start-up company called G enentech, the world's first biotechnology company, participated in the competition to manufacture synthetic insulin. That technique: take DNA that causes insulin production, insert it into E. coli, and turn bacterial cells into small factories that can extract protein chains. Beginner Genentech took the process, won the competition, and in 1979 released a groundbreaking paper explaining the work. In 1982, the US Food and Drug Administration approved the application for humulin, the first synthetic human insulin, and the first biotechnology drug by Eli Lilly and Company.